Diagnosis, FISH, and immunohistochemical data of IG/IRF4-positive cases
| Case no. . | Study . | Diagnosis . | FISH . | Immunohistochemistry . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, y/sex . | IRF4 translocation . | BCL6 break . | MYC break . | t(14;18)/BCL2 break . | CD5 . | CD10 . | MUM1 . | BCL6 . | BCL2 . | BLIMP . | ki67 . | Hans* classifier16 . | GEP . | |||
| 1-MPI093 | MMML | DLBCL, NOS | 12/female | IGL/IRF4 | − | − | − | - | NA | ++ | ++ | + | NA | + | NA | GCB |
| 2-MPI124 | MMML | DLBCL, cb | 62/female | IGH/IRF4 | Split | − | − | ++ | - | ++ | ++ | ++ | - | ++ | Non-GC | Unclassified |
| 3-MPI233 | MMML | DLBCL, cb | 8/female | IGH/IRF4† | − | − | − | ++ | - | ++ | ++ | ++ | NA | ++ | Non-GC | GCB |
| 4-MPI276 | MMML | DLBCL, cb | 79/female | IGH/IRF4 | Split | − | − | - | - | ++ | + | - | NA | ++ | Non-GC | GCB |
| 5-MPI571 | MMML | DLBCL, cb | 7/female | IGH/IRF4† | − | − | − | - | ++ | ++ | + | ++ | NA | + | GC | GCB |
| 6-MPI581 | MMML | DLBCL, NOS | 6/female | IGH/IRF4 | − | − | − | - | ++ | ++ | ++ | ++ | - | + | GC | GCB |
| 7-MPI584 | MMML | DLBCL, cb | 15/male | IGH/IRF4 | − | − | − | - | ++ | ++ | ++ | - | NA | ++ | GC | GCB |
| 8 | BFM | FL3B | 7/male | IGH/IRF4 | − | − | − | - | + | + | ++ | ++ | NA | + | GC | NA |
| 9 | BFM | DLBCL, cb | 15/male | IGH/IRF4 | Split | − | − | - | + | ++ | ++ | - | NA | + | GC | NA |
| 10 | BFM | DLBCL, cb | 4/female | IGH/IRF4 | − | − | − | - | ++ | ++ | + | + | - | ++ | GC | NA |
| 11 | BFM | DLBCL, cb | 10/male | IGL/IRF4 | − | − | − | - | ++ | + | ++ | - | - | ++ | GC | NA |
| 12 | BFM | FL3B/DLBCL | 5/male | IGH/IRF4 | − | − | − | - | ++ | ++ | ++ | + | NA | + | GC | NA |
| 13 | BFM | DLBCL, cb | 9/male | IGH/IRF4 | Split | − | − | - | ++ | ++ | ++ | - | - | ++ | GC | NA |
| 14 | BFM | FL3A/DLBCL | 12/male | IGH/IRF4 | − | Split | − | + | + | ++ | + | + | - | ++ | Non-GC | NA |
| 15 | Routine | B-cell lymphoma, NOS‡ | 72/male | IGK/IRF4 | − | − | − | + | - | ++ | NA | NA | NA | NA | Non-GC | NA |
| 16 | DSHNHL | FL3B/DLBCL | 22/male | IGH/IRF4 | − | − | − | - | + | ++ | ++ | - | - | ++ | GC | NA |
| 17 | DSHNHL | DLBCL, cb | 20/male | IGH/IRF4 | Split | − | − | ++ | - | ++ | + | ++ | - | + | Non-GC | NA |
| 18 | DSHNHL | FL3B | 42/female | IGH/IRF4 | Split | − | − | - | - | ++ | NA | ++ | NA | ++ | Non-GC | NA |
| 19 | DSHNHL | DLBCL, cb | 28/male | IGH/IRF4 | Split | − | − | - | NA | + | - | - | - | ++ | NA | NA |
| 20 | BFM | FL3B/DLBCL | 8/female | IGH/IRF4 | − | − | − | + | + | ++ | + | ++ | - | ++ | GC | NA |
| Predicted 1 MPI059 | MMML | DLBCL, NOS | 31/male | Atypical IRF4 break (no IG) | − | − | − | - | ++ | ++ | ++ | - | NA | + | GC | GCB |
| Predicted 2 MPI514 | MMML | DLBCL, cb | 79/female | Atypical IGH/IRF4§ | − | − | − | ++ | - | ++ | + | ++ | NA | ++ | Non-GC | GCB |
| Predicted 3 MPI823 | MMML | DLBCL, poly | 49/male | IGH/IRF4 | Split | − | − | - | - | ++ | ++ | ++ | + | ++ | Non-GC | Unclassified |
| Extra+ | BFM | FL3A | 14/male | IRF4 break, IGH break | NA | NA | NA | - | + | NA | + | NA | NA | ++ | GC | NA |
| Case no. . | Study . | Diagnosis . | FISH . | Immunohistochemistry . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, y/sex . | IRF4 translocation . | BCL6 break . | MYC break . | t(14;18)/BCL2 break . | CD5 . | CD10 . | MUM1 . | BCL6 . | BCL2 . | BLIMP . | ki67 . | Hans* classifier16 . | GEP . | |||
| 1-MPI093 | MMML | DLBCL, NOS | 12/female | IGL/IRF4 | − | − | − | - | NA | ++ | ++ | + | NA | + | NA | GCB |
| 2-MPI124 | MMML | DLBCL, cb | 62/female | IGH/IRF4 | Split | − | − | ++ | - | ++ | ++ | ++ | - | ++ | Non-GC | Unclassified |
| 3-MPI233 | MMML | DLBCL, cb | 8/female | IGH/IRF4† | − | − | − | ++ | - | ++ | ++ | ++ | NA | ++ | Non-GC | GCB |
| 4-MPI276 | MMML | DLBCL, cb | 79/female | IGH/IRF4 | Split | − | − | - | - | ++ | + | - | NA | ++ | Non-GC | GCB |
| 5-MPI571 | MMML | DLBCL, cb | 7/female | IGH/IRF4† | − | − | − | - | ++ | ++ | + | ++ | NA | + | GC | GCB |
| 6-MPI581 | MMML | DLBCL, NOS | 6/female | IGH/IRF4 | − | − | − | - | ++ | ++ | ++ | ++ | - | + | GC | GCB |
| 7-MPI584 | MMML | DLBCL, cb | 15/male | IGH/IRF4 | − | − | − | - | ++ | ++ | ++ | - | NA | ++ | GC | GCB |
| 8 | BFM | FL3B | 7/male | IGH/IRF4 | − | − | − | - | + | + | ++ | ++ | NA | + | GC | NA |
| 9 | BFM | DLBCL, cb | 15/male | IGH/IRF4 | Split | − | − | - | + | ++ | ++ | - | NA | + | GC | NA |
| 10 | BFM | DLBCL, cb | 4/female | IGH/IRF4 | − | − | − | - | ++ | ++ | + | + | - | ++ | GC | NA |
| 11 | BFM | DLBCL, cb | 10/male | IGL/IRF4 | − | − | − | - | ++ | + | ++ | - | - | ++ | GC | NA |
| 12 | BFM | FL3B/DLBCL | 5/male | IGH/IRF4 | − | − | − | - | ++ | ++ | ++ | + | NA | + | GC | NA |
| 13 | BFM | DLBCL, cb | 9/male | IGH/IRF4 | Split | − | − | - | ++ | ++ | ++ | - | - | ++ | GC | NA |
| 14 | BFM | FL3A/DLBCL | 12/male | IGH/IRF4 | − | Split | − | + | + | ++ | + | + | - | ++ | Non-GC | NA |
| 15 | Routine | B-cell lymphoma, NOS‡ | 72/male | IGK/IRF4 | − | − | − | + | - | ++ | NA | NA | NA | NA | Non-GC | NA |
| 16 | DSHNHL | FL3B/DLBCL | 22/male | IGH/IRF4 | − | − | − | - | + | ++ | ++ | - | - | ++ | GC | NA |
| 17 | DSHNHL | DLBCL, cb | 20/male | IGH/IRF4 | Split | − | − | ++ | - | ++ | + | ++ | - | + | Non-GC | NA |
| 18 | DSHNHL | FL3B | 42/female | IGH/IRF4 | Split | − | − | - | - | ++ | NA | ++ | NA | ++ | Non-GC | NA |
| 19 | DSHNHL | DLBCL, cb | 28/male | IGH/IRF4 | Split | − | − | - | NA | + | - | - | - | ++ | NA | NA |
| 20 | BFM | FL3B/DLBCL | 8/female | IGH/IRF4 | − | − | − | + | + | ++ | + | ++ | - | ++ | GC | NA |
| Predicted 1 MPI059 | MMML | DLBCL, NOS | 31/male | Atypical IRF4 break (no IG) | − | − | − | - | ++ | ++ | ++ | - | NA | + | GC | GCB |
| Predicted 2 MPI514 | MMML | DLBCL, cb | 79/female | Atypical IGH/IRF4§ | − | − | − | ++ | - | ++ | + | ++ | NA | ++ | Non-GC | GCB |
| Predicted 3 MPI823 | MMML | DLBCL, poly | 49/male | IGH/IRF4 | Split | − | − | - | - | ++ | ++ | ++ | + | ++ | Non-GC | Unclassified |
| Extra+ | BFM | FL3A | 14/male | IRF4 break, IGH break | NA | NA | NA | - | + | NA | + | NA | NA | ++ | GC | NA |
Extra+ indicates additional IRF4-break-positive case; DSHNHL, German high-grade Lymphoma Study Group; BFM, Berlin-Frankfurt-Münster NHL trials; FL 3A/B, follicular lymphoma grade 3A or 3B; NOS, not otherwise specified; cb, centroblastic; poly, polymorphic; −: negative; ++, high expression (> 50%); +, moderate expression (25%-50%); -, no expression (< 25%); NA, not available; and GEP, gene expression profiling.
Hans classifier was applied to lymphomas other that DLBCLs, though not developed originally for those.
Translocation cloned.
Transformation, transition in a secondary malignant B-cell lymphoma.
Lack of der(6)t(6;14)(p25;q32).